ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

imeglimin

Also written as “Imeglimin” and “Imeglimin Hydrochloride Film Coated Tablet”.

Its studies are mostly in Diabetes Mellitus, Type 2, led by 2 companies.

Drug pageImeglimin: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Sep 19, 20137 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Poxelits history only60 open or runningphase 2since Sep 19, 2013Sep 19, 2013none ahead
Humanis Saglık Anonim Sirketi10 open or runningphase 1since Jul 1, 2026Jul 1, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Humanis Saglık Anonim Sirketi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 1, 2026First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT07691177 · 40 enrolled · India

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Humanis Saglık Anonim Sirketi leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07691177Diabetes Mellitus, Type 2 · India1CompletedMar 27, 202640

How it is read

Names in the registry

  • “Imeglimin”, 6 entries
  • “Imeglimin Hydrochloride Film Coated Tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.